000			04147nam a22003855i 4500
001			282878
003			MX-SnUAN
005			20160429154210.0
007			cr nn 008mamaa
008			150903s2008 ne | o |||| 0|eng d
020			_a9781402086960 _99781402086960
024	7		_a10.1007/9781402086960 _2doi
035			_avtls000336110
039		9	_a201509030257 _bVLOAD _c201404300311 _dVLOAD _y201402041341 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC261-271
100	1		_aStigbrand, Torgny. _eeditor. _9309969
245	1	0	_aTargeted Radionuclide Tumor Therapy : _bBiological Aspects / _cedited by Torgny Stigbrand, Jörgen Carlsson, Gregory P. Adams.
264		1	_aDordrecht : _bSpringer Netherlands, _c2008.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
500			_aSpringer eBooks
505	0		_ato Radionuclide Therapy -- Therapeutically Used Targeted Antigens in Radioimmunotherapy -- EGFR-Family Expression and Implications for Targeted Radionuclide Therapy -- Targeting Tumours with Radiolabeled Antibodies -- Antibody Fragments Produced by Recombinant and Proteolytic Methods -- Novel Alternative Scaffolds and Their Potential Use for Tumor Targeted Radionuclide Therapy -- Peptides for Radionuclide Therapy -- Choice of Radionuclides and Radiolabelling Techniques -- High-LET-Emitting Radionuclides for Cancer Therapy -- Targeted High-LET Therapy of Bone Metastases -- The Auger Effect in Molecular Targeting Therapy -- Radiation Induced Cell Deaths -- Radiation Induced DNA-Damage/Repair and Associated Signaling Pathways -- Radiation Induced DNA Damage Checkpoints -- Cancer Stem Cells and Radiation -- Effects of Low Dose-Rate Radiation on Cellular Survival -- Bystander Effects and Radionuclide Therapy -- Enhancing the Efficiency of Targeted Radionuclide Therapy -- Low Dose Hyper-Radiosensitivity: A Historical Perspective -- Clinical Radionuclide Therapy -- Developmental Trends in Targeted Radionuclide Therapy: Biological Aspects.
520			_aThe last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future. The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology. It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aCarlsson, Jörgen. _eeditor. _9309970
700	1		_aAdams, Gregory P. _eeditor. _9309971
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781402086953
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4020-8696-0 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c282878 _d282878